I4V-MC-JAJJ: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Delay Stage 3 Type 1 Diabetes in At-risk Participants Aged ≥1 to <36 Years

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521797-34-00

Acronym

I4V-MC-JAJJ

Enrollment

Registered

2025-12-23

Start date

2026-01-20

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 1

Brief summary

Time from Baseline to Diagnosis of Stage 3 Type 1 Diabetes [Time Frame: Baseline up to approximately 5 years]

Interventions

DRUGPlacebo to match LY

DRUGBARICITINIB

DRUGBaricitinib

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Time from Baseline to Diagnosis of Stage 3 Type 1 Diabetes [Time Frame: Baseline up to approximately 5 years]	—

Countries

Belgium, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Portugal, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026